Clinical trial
Study to Assess the Safety and Efficacy of NRP104 in Adults With…
NCT00334880 · New River Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00334880 |
|---|---|
| Title | Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) |
| Official title | A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) |
| Lead sponsor | New River Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders |
| Intervention type | Drug |
| Interventions | NRP104 |
| Enrollment | 420 |
| Start date | May 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Jun 8, 2006 |
| Last update posted | Jul 2, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: